The UCL Technology Fund is in line for an exit from gene therapy developer Orchard Therapeutics, which has raised more than $290m in equity funding.
UK-based genetic medicine developer Orchard Therapeutics has filed to raise approximately $173m in an initial public offering that will allow the UCL Technology Fund, the university venture fund of University College of London, to exit.
Orchard is developing gene therapy treatments for serious and life-threatening rare diseases, focusing on neurometabolic disorders, immune deficiencies and hemoglobinopathies.
The IPO proceeds will support registrational trials for a range of drug candidates including five lentiviral product candidates currently in clinical development.
